Sandra P D'Angelo, MD

Sarcoma & Merkel cell carcinoma Medical oncologist l Immunotherapy expert l Memorial Sloan Kettering Cancer Center l Tweets are my own

[Memorial Sloan Kettering Cancer Center @MSKCancerCenter]

A powerhouse group representing MSK at the #ASCO26 plenary. 💙

[Patrick Schöffski @schoffski]

Liposarcoma in the holy grail of oncology - the Plenary Session at the ASCO Annual Meeting 2026. Congratulations to Mark A. Dickson and all SARC041 investigators!

[AACR @AACR]

Sandra P. D’Angelo, Alexander N. Shoustari, and Mark Yarchoan will discuss "Harnessing Immunotherapy for Rare Cancers" in a plenary session at the AACR Conference on Rare Cancers (July 18-20, Vancouver).
https://t.co/4SJGhhjSPY
#AACRrarecancers26 @sandrapdangelo @MarkYarchoan

[OncoDaily @oncodaily]

Don’t Just Attend ASCO — Be at the Right Sessions

🌍 𝐆𝐥𝐨𝐛𝐚𝐥 𝐕𝐨𝐢𝐜𝐞𝐬 𝐢𝐧 𝐒𝐚𝐫𝐜𝐨𝐦𝐚 — 𝐋𝐢𝐯𝐞 𝐚𝐭 𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔

OncoDaily Grand Rounds: Sarcoma Edition

📅 May 29
🕒 – pm
📍 Hilton Chicago

@sandrapdangelo • @herbloong • @BrotoJavier • @RobinL_Jones

Featuring leading experts shaping the field today.

🤝Foundational partner: @EliLillyandCo

🥉 Bronze Sponsor: @USWorldMeds

🔗Register: https://t.co/ew6UhcEhZi

🔗 https://t.co/pbk5Ubm9Si

#OncoDailyGrandRoundsSarcoma

[Sandra P D'Angelo, MD @sandrapdangelo]

These data support continued biomarker driven development of CDK4/6 based combinations in DDLPS to improve patient selection, deepen responses, and building more effective therapeutic strategies for this rare sarcoma. #Sarcoma #Liposarcoma #Immunotherapy @MSK_DeptOfMed @WTapMD

[Sandra P D'Angelo, MD @sandrapdangelo]

1/
Proud to share our phase 2 study of palbociclib + retifanlimab in advanced dedifferentiated liposarcoma #DDLPS. This work builds on MSK’s longstanding effort to improve outcomes in DDLPS — from CDK4/6 inhibitor monotherapy, to immunotherapy, to rational combinations.

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: "Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma" https://t.co/CwmHXVRQ1p
@sandrapdangelo @ESeffar @MSKCancerCenter @WTapMD

[Sandra P D'Angelo, MD @sandrapdangelo]

This study is part of a broader MSK DDLPS legacy — from Dr. Mark Dickson’s foundational palbociclib and abemaciclib work (@ASCO 2026 plenary), to immunotherapy studies, to current rational combinations including palbociclib + MEK inhibition led by Dr. Babatunde and Dr. Tap.

[OncoDaily IO @OncoDailyIO]

Moving Immunotherapy Toward Biomarker-Driven Precision Care - Sandra D'Angelo (@sandrapdangelo)

https://t.co/KExVObjS7i

#OncoDaily #Oncology #Cancer #Health #Medicine #Immunotherapy #MedX

[Sandra P D'Angelo, MD @sandrapdangelo]

This study helps move sarcoma immunotherapy toward biomarker-driven precision care. By integrating circulating immune profiles, tumor microenvironment features, and digital pathology, we identify signals that may help predict who is most likely to benefit from ICB.

[Clinical Cancer Research @CCR_AACR]

Now online: Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma https://t.co/hzpFNQeUdr

[Herbert Loong, MBBS, FASCO @herbloong]

The #statusquo of #immunotherapy was challenged at @myesmo #ESMORareCancer26 during a dedicated session. Kicked off by Prof. #AntoineItaliano outlining 'established' and 'emerging' #biomarkers and #immune profiling, together with on-going projects in this field

[Sandra P D'Angelo, MD @sandrapdangelo]

Palbociclib → retifanlimab in DDLPS shows immune‐related toxicity with sequential dosing, prompting change to concurrent dosing. Prelim single-cell + flow analyses reveal cell-cycle suppression, senescence induction and T/B-cell infiltration. Analysis of final cohort pending.

[Cancer Research Communications @CRC_AACR]

Recently published:
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated #Liposarcoma, by Evan Rosenbaum et al. https://t.co/qTw5fR4xI3
@sandrapdangelo @MSKCancerCenter @WeillCornell #Sarcoma #OpenAccess

[ESMO - Eur. Oncology @myESMO]

#ESMO25: Adding #immunotherapy to radiotherapy improved rates of pathological response in resectable #sarcoma, but #biomarkers and histology-focused trials are needed to further improve outcomes.
Read more #ESMODailyReporter 📌 https://t.co/1IbgwtYLju

@sandrapdangelo

[CTOS @ctosociety]

#CTOS2025 is not only about great science, it's also a perfect opportunity for mentorship for trainees and young fellows!
Don't miss the 🌅 Sunrise Mentorship Session on Nov 13, 7.00 am ( breakfast and coffee will be served ☕)!
Check topics and mentors 🧑‍🏫on the graphic⬇️